

Fig 5-S6




Figure 5–Figure Supplement 6. Cell proliferation regulation by JAK inhibitor.
The *TP53/FXR2* co-deletion cancer cell lines (H358, KATOIII) and wild type cancer lines (AGS, A549) are treated with JAKi S-Ruxolitinib at 1 μM for 5 days. Cell proliferation rate is determined by MTS assay. The cell proliferation rate in MTS was determined by measuring absorbance at 490nm (Y axis). Data represent mean ± s.d. from three independent experiments.